Literature DB >> 18621762

Management of breast cancer--Part II.

Nicholas C Turner1, Alison L Jones.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18621762      PMCID： PMC2483889          DOI： 10.1136/bmj.a540

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  29 in total

1.  Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  2000-05-20       Impact factor: 79.321

2.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

3.  Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

Authors:  Paul E Goss; James N Ingle; Silvana Martino; Nicholas J Robert; Hyman B Muss; Martine J Piccart; Monica Castiglione; Dongsheng Tu; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Joseph L Pater
Journal:  J Natl Cancer Inst       Date:  2005-09-07       Impact factor: 13.506

4.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

Authors:  A Howell; J Cuzick; M Baum; A Buzdar; M Dowsett; J F Forbes; G Hoctin-Boes; J Houghton; G Y Locker; J S Tobias
Journal:  Lancet       Date:  2005 Jan 1-7       Impact factor: 79.321

5.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

6.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

7.  Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Authors:  Vered Stearns; Michael D Johnson; James M Rae; Alan Morocho; Antonella Novielli; Pankaj Bhargava; Daniel F Hayes; Zeruesenay Desta; David A Flockhart
Journal:  J Natl Cancer Inst       Date:  2003-12-03       Impact factor: 13.506

8.  A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.

Authors:  Xiao-Jun Ma; Zuncai Wang; Paula D Ryan; Steven J Isakoff; Anne Barmettler; Andrew Fuller; Beth Muir; Gayatry Mohapatra; Ranelle Salunga; J Todd Tuggle; Yen Tran; Diem Tran; Ana Tassin; Paul Amon; Wilson Wang; Wei Wang; Edward Enright; Kimberly Stecker; Eden Estepa-Sabal; Barbara Smith; Jerry Younger; Ulysses Balis; James Michaelson; Atul Bhan; Karleen Habin; Thomas M Baer; Joan Brugge; Daniel A Haber; Mark G Erlander; Dennis C Sgroi
Journal:  Cancer Cell       Date:  2004-06       Impact factor: 31.743

9.  Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.

Authors:  Richard Eastell; Judith E Adams; Robert E Coleman; Anthony Howell; Rosemary A Hannon; Jack Cuzick; John R Mackey; Matthias W Beckmann; Glen Clack
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

10.  Repeated observation of breast tumor subtypes in independent gene expression data sets.

Authors:  Therese Sorlie; Robert Tibshirani; Joel Parker; Trevor Hastie; J S Marron; Andrew Nobel; Shibing Deng; Hilde Johnsen; Robert Pesich; Stephanie Geisler; Janos Demeter; Charles M Perou; Per E Lønning; Patrick O Brown; Anne-Lise Børresen-Dale; David Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-26       Impact factor: 12.779
View more
  6 in total

1.  Lipophilic statin use and risk of breast cancer subtypes.

Authors:  Stephan Woditschka; Laurel A Habel; Natalia Udaltsova; Gary D Friedman; Weiva Sieh
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-08-20       Impact factor: 4.254

2.  FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo.

Authors:  Rachel Sharpe; Alex Pearson; Maria T Herrera-Abreu; Damian Johnson; Alan Mackay; Jonathan C Welti; Rachael Natrajan; Andrew R Reynolds; Jorge S Reis-Filho; Alan Ashworth; Nicholas C Turner
Journal:  Clin Cancer Res       Date:  2011-06-28       Impact factor: 12.531

3.  Phloroglucinol suppresses metastatic ability of breast cancer cells by inhibition of epithelial-mesenchymal cell transition.

Authors:  Rae-Kwon Kim; Yongjoon Suh; Ki-Chun Yoo; Yan-Hong Cui; Eunji Hwang; Hyun-Jin Kim; Ju-Seop Kang; Min-Jung Kim; Young Yiul Lee; Su-Jae Lee
Journal:  Cancer Sci       Date:  2014-12-03       Impact factor: 6.716

4.  Activation of KRAS promotes the mesenchymal features of basal-type breast cancer.

Authors:  Rae-Kwon Kim; Yongjoon Suh; Ki-Chun Yoo; Yan-Hong Cui; Hyeonmi Kim; Min-Jung Kim; In Gyu Kim; Su-Jae Lee
Journal:  Exp Mol Med       Date:  2015-01-30       Impact factor: 8.718

5.  HET0016, a selective inhibitor of 20-HETE synthesis, decreases pro-angiogenic factors and inhibits growth of triple negative breast cancer in mice.

Authors:  Thaiz Ferraz Borin; Debora A P C Zuccari; Bruna V Jardim-Perassi; Lívia C Ferreira; A S M Iskander; Nadimpalli Ravi S Varma; Adarsh Shankar; Austin M Guo; Guillermo Scicli; Ali S Arbab
Journal:  PLoS One       Date:  2014-12-30       Impact factor: 3.240

6.  Certification of breast centres in Germany: proof of concept for a prototypical example of quality assurance in multidisciplinary cancer care.

Authors:  Sara Y Brucker; Michael Bamberg; Walter Jonat; Matthias W Beckmann; Andreas Kämmerle; Rolf Kreienberg; Diethelm Wallwiener
Journal:  BMC Cancer       Date:  2009-07-14       Impact factor: 4.430
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.